Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.EBioMedicine · 2024
   Trial
2. An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
   Article
3. Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review.International journal of molecular sciences · 2025
   Review
4. Crosstalk Between Cancer-associated Fibroblasts and Myeloid Cells Shapes the Heterogeneous Microenvironment of Gastric Cancer.Current genomics · 2024
   Article
5. Tri©DB: an integrated platform of knowledgebase and reporting system for cancer precision medicine.Journal of translational medicine · 2023
   Article
6. Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies.JCO precision oncology · 2022
   Article
7. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.Gut · 2022
   Article
8. KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves.BMC medical research methodology · 2022
   Article
9. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination.Gut · 2021
   Article
10. Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review.Journal of gastrointestinal oncology · 2020
    Article
11. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers.Frontiers in oncology · 2020
    Review

Corrections and comments

• Comment on
  Negative Hyperselection of Patients With2019

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as